RESUMO
BACKGROUND: Frequency, microbiology, and outcomes of necrotizing soft tissue infections vary based on locoregional and environmental factors; however, there has been no global survey of these patterns. We performed a systematic review/meta-analysis on published reports of necrotizing soft tissue infections from across the globe. METHODS: Peer-reviewed empirical studies examining rates of polymicrobial and monomicrobial necrotizing soft tissue infections with microbial isolation and overall mortality rate were extracted along with geographic location using PubMed, Scopus, ProQuest, and Web of Science. Random-effects meta-analyses and sensitivity analyses were performed, adjusting for publication bias. Meta-regression analyses examined moderator effects of risk factors. RESULTS: One hundred and five studies (8,718 total patients) were included. Pooled prevalence of polymicrobial and monomicrobial infections were 53% and 37.9%, respectively. Truncal necrotizing soft tissue infections were commonly polymicrobial (P < .001), whereas monomicrobial infections prevailed in extremities (P = .008). Global prevalence of monomicrobial necrotizing soft tissue infections was observed to increase by 1.1% annually (P = .003). Staphylococcus aureus was the most common organism globally and in North America, Asia, the Middle East, and Africa, followed by Streptococcus pyogenes and Escherichia coli. Methicillin-resistant S. aureus accounted for 16% of necrotizing soft tissue infections globally. Overall mortality was 23.1%, observed to decline globally over the last decade (P = .020). No regional differences were noted for mortality. CONCLUSION: Although polymicrobial infections remain predominant worldwide, the incidence of monomicrobial infections is increasing. The observed decline in necrotizing soft tissue infection-related mortality is encouraging and may reflect advances in management, despite major variations in available healthcare resources globally.
Assuntos
Coinfecção/epidemiologia , Infecções por Escherichia coli/epidemiologia , Infecções dos Tecidos Moles/epidemiologia , Infecções Estafilocócicas/epidemiologia , Infecções Estreptocócicas/epidemiologia , Coinfecção/diagnóstico , Coinfecção/microbiologia , Coinfecção/terapia , Escherichia coli/isolamento & purificação , Infecções por Escherichia coli/diagnóstico , Infecções por Escherichia coli/microbiologia , Infecções por Escherichia coli/terapia , Carga Global da Doença/tendências , Humanos , Incidência , Mortalidade/tendências , Necrose/epidemiologia , Necrose/microbiologia , Necrose/terapia , Infecções dos Tecidos Moles/diagnóstico , Infecções dos Tecidos Moles/microbiologia , Infecções dos Tecidos Moles/terapia , Infecções Estafilocócicas/diagnóstico , Infecções Estafilocócicas/microbiologia , Infecções Estafilocócicas/terapia , Staphylococcus aureus/isolamento & purificação , Infecções Estreptocócicas/diagnóstico , Infecções Estreptocócicas/microbiologia , Infecções Estreptocócicas/terapia , Streptococcus pyogenes/isolamento & purificação , Resultado do TratamentoRESUMO
Children/adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL) have an excellent prognosis but relapses still occur. While chromosomal aberrations and/or clonal immunoglobulin (Ig) gene rearrangements may indicate risk of failure, a more universal approach was developed to detect minimal disease (MD). Children/adolescents with intermediate-risk B-NHL were treated with French-British-American/Lymphome Malins de Burkitt 96 (FAB/LMB96) B4 modified chemotherapy and rituximab. Specimens from diagnosis, end of induction (EOI), and end of therapy (EOT) were assayed for MD. Initial specimens were screened for IGHV family usage with primer pools followed by individual primers to identify MD. Thirty-two diagnostic/staging specimens screened positive with primer pools and unique IGHV family primers were identified. Two patients relapsed; first relapse (4 months from diagnosis) was MD-positive at EOI, the second (36 months from diagnosis) was MD-positive at EOT. At EOI, recurrent rates were similar between the MRD-positive and MRD-negative patients (P = 0·40). At EOT, only 13/32 patients had MRD data available with one relapse in the MRD-positive group and no recurrences in the MRD-negative group (P = 0·077). The study demonstrated molecular-disseminated disease in which IgIGHV primer pools could be used to assess MD. This feasibility study supports future investigations to assess the validity and significance of MD screening in a larger cohort of patients with intermediate-risk mature B-NHL.
Assuntos
Linfoma de Células B/tratamento farmacológico , Adolescente , Anticorpos Monoclonais Murinos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Criança , Métodos Epidemiológicos , Genes de Cadeia Pesada de Imunoglobulina , Genes Neoplásicos , Humanos , Linfoma de Células B/genética , Linfoma de Células B/patologia , Estadiamento de Neoplasias , Neoplasia Residual , Recidiva , Rituximab , Adulto JovemRESUMO
BACKGROUND: The trajectory of Heath-Related Quality of Life (HRQoL) in pediatric recipients who have undergone hematopoietic stem cell transplantation (HSCT), as well as the demographic and medical factors that predict HRQoL, has lagged behind the adult research. METHODS: A prospective longitudinal study of HRQoL in pediatric HSCT recipients was conducted with 95 patients at the Columbia University Medical Center between 2002 and 2009. Both children and parents completed the PedsQL 4.0 prior to HSCT and at days 100, 180, and 365-post-HSCT. RESULTS: The majority of patients and their parents reported linear improvements in HRQoL in the first year post-transplant; however, a portion of patients were in the at-risk group at each time point. Latent growth modeling was utilized to examine demographic and medical factors that predicted initial HRQoL and its trajectory. Older age at transplant significant predicted lowered HRQoL at baseline for self- and parent-report. Female gender significantly impacted lowered self-reported physical HRQoL over time. Ethnicity was a significant predictor of HRQoL at baseline and over time for self- and parent-report, with African-American children reporting the highest HRQoL; whereas, the worst decline in psychosocial HRQoL was often reported by parents and children of Asian descent. CONCLUSION: This research identifies the significant impact of ethnicity upon HRQoL following pediatric HSCT. It is likely that an individual's pre-morbid experiences and expectations, particularly with regard to culture, behaviors, and values, influence the parent and child's perceptions and expectations of the HSCT process.
Assuntos
Transplante de Células-Tronco Hematopoéticas/psicologia , Qualidade de Vida/psicologia , Adolescente , Povo Asiático , População Negra , Criança , Pré-Escolar , Feminino , Doenças Hematológicas/cirurgia , Humanos , Estudos Longitudinais , Masculino , Inquéritos e Questionários , População BrancaRESUMO
Population health is concerned with reducing health inequities, defined as being unfair and avoidable differences in health. The equity-effectiveness framework is described and illustrated; this is an evidence-based approach to assessing the effects of programmes and policies on health equity. Such framework also assesses barriers and facilitators for improving health equity using four factors: access, diagnostic accuracy, adherence and compliance. This framework emphasises the importance of transferring knowledge for designing and implementing clinical and public health interventions to improve health in all socioeconomic strata, based on the best available evidence. The World Health Organisation Collaborating Centre on Health Technology Assessment is now using this framework for organising the components of its equity-orientated, evidence-based toolkit.
La salud poblacional es concebida como la reducción de las inequidades en salud, definida como las diferencias evitables e injustas en salud. Nosotros describimos e ilustramos el marco de equidad-efectividad; una aproximación basada en evidencia para evaluar los efectos de programas y políticas sobre la equidad en salud. Este marco además evalúa las barreras y los facilitadores para mejorar la equidad a través de cuatro factores: acceso, exactitud diagnóstica, adherencia y conformidad. Este marco enfatiza la importancia de la transferencia de conocimiento para diseñar e implementar intervenciones en salud públicas y clínicas para mejorar la salud a través de todos los estratos socioeconómicos, basados en la mejor evidencia disponible. El Centro Colaborativo de la Organización Mundial de la Salud sobre Evaluación de Tecnologías Sanitarias está utilizando actualmente este marco para organizar su Paquete de Herramientas basadas en evidencia y orientadas por la equidad.
Assuntos
Humanos , Atenção à Saúde/organização & administração , Disparidades em Assistência à Saúde , Fatores SocioeconômicosRESUMO
BACKGROUND: Using data from the Healthcare Cost and Utilization Project 2004 Nationwide Inpatient Sample, we estimated inpatient resource utilization among patients with hematologic malignancies, with and without concomitant acute renal failure. PATIENTS AND METHODS: We analyzed patients with hematologic malignancies (excluding Hodgkin disease), acute renal failure, and renal dialysis. Subgroup analyses were performed on specific types of hematologic malignancies, with and without acute renal failure and with and without renal dialysis. RESULTS: Among those with hematologic malignancies, acute renal failure, with and without concomitant renal dialysis, increases inpatient length of stay and costs. Mean length of stay and costs for all patients with acute renal failure and renal dialysis (n = 5148), acute renal failure without renal dialysis (n = 27,654), and no acute renal failure or renal dialysis (n = 350,601) were 17.6, 12.2, and 7.4 days, and $44,619, $25,638, and $13,947, respectively. CONCLUSION: Treatment of hematologic malignancies and concomitant acute renal failure and renal dialysis places an economic burden on the health care system. Reducing the incidence of acute renal failure and concomitant renal dialysis with supportive care in patients with hematologic malignancies can reduce inpatient resource use.
Assuntos
Injúria Renal Aguda/economia , Custos de Cuidados de Saúde , Neoplasias Hematológicas/economia , Tempo de Internação , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
Population health is concerned with reducing health inequities, defined as being unfair and avoidable differences in health. The equity-effectiveness framework is described and illustrated; this is an evidence-based approach to assessing the effects of programmes and policies on health equity. Such framework also assesses barriers and facilitators for improving health equity using four factors: access, diagnostic accuracy, adherence and compliance. This framework emphasises the importance of transferring knowledge for designing and implementing clinical and public health interventions to improve health in all socioeconomic strata, based on the best available evidence. The World Health Organisation Collaborating Centre on Health Technology Assessment is now using this framework for organising the components of its equity-orientated, evidence-based toolkit.
Assuntos
Atenção à Saúde/organização & administração , Disparidades em Assistência à Saúde , Humanos , Fatores SocioeconômicosRESUMO
A feasibility study was undertaken to identify patient-specific primers (PSPs) from childhood non-Hodgkin lymphoma (NHL) specimens to detect minimal residual disease (MRD). Eleven tumor specimens were amplified using immunoglobulin heavy chain and T-cell receptor primers to identify PSPs, which were then used to evaluate staging/follow-up specimens. Disease was detected in 19 of 21 staging and 16 of 17 follow-up specimens. Among seven patients in remission by 1 month, PSPs identified MRD in follow-up specimens. This study demonstrated the feasibility of PSPs to identify disease in staging and follow-up specimens, which could be used to develop strategies for MRD analysis in a larger setting.